Newer Drug For Lymphoma Cancer
WEDNESDAY, Oct. 4, 2017 (HealthDay News) — A newer drug may beat the standard Lymphoma Cancer Treatment when it comes to battling the blood cancer lymphoma, a clinical trial suggests.The new study found that a drug called obinutuzumab (Gazyva) typically kept the cancer under control longer, versus the standard drug rituximab (Rituxan).After three years, about 80 percent of obinutuzumab patients were showing no signs of Lymphoma Cancer progression or relapse. That compared with roughly 73 percent of rituximab patients, according to the report.Cancer experts said the results, published in the Oct. 5 issue of the New England Journal of Medicine, are a positive step forward.
But they do not necessarily mean obinutuzumab is the better choice for all patients, according to Dr. James Armitage, an oncologist at the University of Nebraska Medical Center, in Omaha.“Obinutuzumab had a modest advantage in progression-free survival,” said Armitage, who co-wrote an editorial published with the study.But the L ymphoma Cancerdrug also tended to cause more side effects than rituximab, he pointed out. And no one knows yet whether it will ultimately help patients live longer.Armitage said “reasonable people” could disagree over which Lymphoma Cancer drug option is better.In the United States, more than 72,000 people are diagnosed with non-Hodgkin lymphoma each year, according to the American Cancer Society (ACS). Follicular lymphoma accounts for roughly 20 percent of those cases.Follicular lymphoma is usually slow-growing and responds well to treatment, according to the ACS — but most patients do eventually relapse.